A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Anzupgo
Synonyms :
Delgocitinib
Class :
Dermatologics, JAK Inhibitors
Brand Name :
Anzupgo
Synonyms :
Delgocitinib
Class :
Dermatologics, JAK Inhibitors
Adult
Dosage Forms & Strengths
Topical cream
2%
Eczema
Apply thin layer topically two times daily to affected areas on wrists and hands
Avoid using more than 30 gm in two weeks
Pediatric
Safety and efficacy not recommended.
Geriatric
Refer to the adult dosing
The pan Janus kinase (JAK) inhibitor delgocitinib targets the activity of each of the four JAK family members in a concentration-dependent manner.
Because they influence the signalling of inflammatory cytokines, the JAK family has been linked to several inflammatory illnesses.
When delgocitinib inhibits the JAK-STAT pathway in human cells, it reduces the signalling of several pro-inflammatory cytokines.
Frequency defined
<1%
Paresthesia
Bacterial skin infections
Leukopenia
Neutropenia
Eczema herpeticum
Herpes zoster
Pruritus
Erythema
None
Contraindications
None
Cautions
Serious infections
Non-melanoma skin cancers
Immunizations
Potential risks related to JAK inhibition
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion in human breastmilk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
The recruitment of signal transducers and activators of transcription (STATs) to cytokine receptors, as well as their activation and subsequent localization to the nucleus are all components of JAK signalling.
It results in the production of genes that respond to cytokines, which causes target cells to undergo biological reactions.
Pharmacodynamics:
Delgocitinib reduces inflammation in inflammatory skin diseases through the inhibition of inflammatory mediator molecular signalling.
It increased keratinocyte terminal differentiation and improved skin barrier function in mouse models of atopic dermatitis.
It improved the clinical symptoms of atopic dermatitis and chronic hand eczema 2 in human clinical studies.
Pharmacokinetics:
Absorption:
It has peak plasma concentration of 1.53 ng/ml.
Distribution:
It shows moderate protein bound up to 22 to 29%.
Metabolism:
It does not go through a lot of metabolisms, while the drug’s primary plasma component remains constant.
Excretion and elimination:
The average half-life of delgocitinib was approximately 21 hours.
Use only for topical application and it is available in cream form.
Avoid by using oral, ophthalmic, or any other routes.
Before applying a thin layer of cream, clean and dry the afflicted areas.
Patient should refrain from touching their mouth, eyes, or other mucous membranes.
If they do, then immediately thoroughly rinse with water.
Generic Name: Delgocitinib
Why do we use delgocitinib?
Delgocitinib is used for the treatment of chronic hand eczema (CHE) in adults.
It is indicated in moderate to severe cases of CHE.
It is effective in those adults whom topical corticosteroids are not recommended or those who not responded well to them.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
